Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04864847Active Not Recruiting

Clinical Validation of the RENISCHEM L-FABP POC Assay

Role: lead

NCT06710262Completed

T-TAS® wS Method Comparison

Role: lead

NCT06087198Completed

Clinical Performance Evaluation of T-TAS®01 HD Chip

Role: lead

NCT03621020Completed

Clinical Performance Evaluation of T-TAS 01 PL Chip

Role: lead

All 4 trials loaded